{"id":"nvp-2203","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL532496","moleculeType":"Small molecule","molecularWeight":"600.77"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, NVP-2203 prevents the interaction between PD-1 and its ligands, leading to the activation of T cells and enhanced anti-tumor immune response.","oneSentence":"NVP-2203 is a small molecule that targets the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:37.852Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT05856487","phase":"PHASE3","title":"To Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients","status":"UNKNOWN","sponsor":"NVP Healthcare","startDate":"2023-06-30","conditions":"Cardiovascular Diseases","enrollment":228},{"nctId":"NCT05725252","phase":"PHASE1","title":"To Evaluate the Safety and the Pharmacokinetics of NVP-2203","status":"COMPLETED","sponsor":"NVP Healthcare","startDate":"2023-05-28","conditions":"Healthy Volunteers","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NVP-2203","genericName":"NVP-2203","companyName":"NVP Healthcare","companyId":"nvp-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NVP-2203 is a small molecule that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}